ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2026)
ARS Pharmaceuticals (SPRY) posted FCF Margin of 198.17% for Q1 2026, down 28.0% sequentially from 154.82% in Q4 2025, and up 31398.0% YoY from N/an in Q1 2025.
ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported FCF Margin for 5 years, with the latest figure at 198.17% in Q1 2026.
- Quarterly FCF Margin rose 31398.0% year-over-year to 198.17% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 177.11% (down 15544.0% YoY) and the FY2025 annual result came in at 203.14%, down 21771.0% from the prior year.
- FCF Margin eased to 198.17% in Q1 2026 per SPRY's latest filing, from 154.82% in the prior quarter.
- Over five years, FCF Margin peaked at 48.17% in Q4 2024 and troughed at 165670.0% in Q2 2023.
- A 5-year average of 18287.87% and a median of 712.19% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2024: FCF Margin tumbled 16416224 bps in 2023, then jumped 16423080 bps in 2024.
- Over 5 years, FCF Margin stood at 3022.22% in 2022, then slumped by 5382 bps to 165670.0% in 2023, then jumped by 100 bps to 48.17% in 2024, then plunged by 421 bps to 154.82% in 2025, then decreased by 28 bps to 198.17% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 198.17%, 154.82%, and 127.77% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -181.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -181.02% |
| Mar 31, 2026 | -198.17% |
| Dec 31, 2025 | -154.82% |
| Sep 30, 2025 | -127.77% |
| Jun 30, 2025 | -288.61% |
| Mar 31, 2025 | -512.14% |
| Dec 31, 2024 | 48.17% |
| Sep 30, 2024 | -712.19% |
| Jun 30, 2024 | -1,439.20% |
| Jun 30, 2023 | -165,670.00% |
| Mar 31, 2023 | -63,110.00% |
| Sep 30, 2022 | -3,022.22% |
| Jun 30, 2022 | -1,507.76% |
| Mar 31, 2022 | -1,047.66% |